Regeneron

YTD

ALL

Trade Regeneron 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About REGN

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara.

CEO

Leonard S. Schleifer

CEOLeonard S. Schleifer

Employees

15,410

Employees15,410

Headquarters

Tarrytown, New York

HeadquartersTarrytown, New York

Founded

1988

Founded1988

Employees

15,410

Employees15,410

REGN Key Statistics

Market cap

63.96B

Market cap63.96B

Price-Earnings ratio

14.81

Price-Earnings ratio14.81

Dividend yield

0.60%

Dividend yield0.60%

Average volume

1.00M

Average volume1.00M

High today

$616.24

High today$616.24

Low today

$598.19

Low today$598.19

Open price

$612.07

Open price$612.07

Volume

2.61M

Volume2.61M

52 Week high

$821.11

52 Week high$821.11

52 Week low

$503.25

52 Week low$503.25

Stock Snapshot

Regeneron(REGN) stock is priced at $603.54, giving the company a market capitalization of 63.96B. It carries a P/E multiple of 14.81 and pays a dividend yield of 0.60%.

During the trading session on 2026-06-18, Regeneron(REGN) shares reached a daily high of $616.24 and a low of $598.19. At a current price of $603.54, the stock is +0.9% higher than the low and still -2.1% under the high.

Trading volume for Regeneron(REGN) stock has reached 2.61M, versus its average volume of 1M.

The stock's 52-week range extends from a low of $503.25 to a high of $821.11.

REGN News

TipRanks 9h

Regeneron Advances First-in-Human Myeloma Combo Trial, Keeping Oncology Pipeline in Focus

Regeneron Pharmaceuticals (REGN) announced an update on their ongoing clinical study. Unlock powerful investing tools and data-driven insights with TipRanks Pr...

TipRanks 1d

Regeneron Shareholders Back Directors, Auditor and Executive Pay

Unlock powerful investing tools and data-driven insights with TipRanks Premium for more confident investment decisions. Discover top stock picks and new invest...

MarketWatch 1d

Regeneron Pharmaceuticals Inc. stock outperforms competitors despite losses on the day - MarketWatch

...

Analyst ratings

74%

of 31 ratings

Buy

74.2%

Hold

25.8%

Sell

More REGN News

Simply Wall St 6d

Regeneron Stock Valuation After WHO Ebola Trial Backing And Expanding R&D Collaborations

Regeneron Pharmaceuticals (REGN) is back in focus after the World Health Organization recommended its antibody therapy maftivimab for Ebola trials, along with r...

People also own

Based on the portfolios of people who own REGN. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.